Production (Stage)
Qualigen Therapeutics, Inc.
QLGN
$3.42
-$0.10-2.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -72.28% | -35.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -72.28% | -35.10% |
| Cost of Revenue | -84.48% | -152.39% | -127.70% | -113.33% | -97.76% |
| Gross Profit | 84.48% | 152.39% | 127.70% | 117.82% | 96.78% |
| SG&A Expenses | -30.98% | -46.09% | -51.22% | -38.75% | -45.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.20% | -46.22% | -37.57% | -33.40% | -37.92% |
| Operating Income | 52.20% | 46.22% | 37.57% | 26.45% | 29.59% |
| Income Before Tax | 50.66% | 42.82% | 31.78% | 20.05% | 17.85% |
| Income Tax Expenses | 550.00% | -210.34% | -172.41% | -86.11% | -90.77% |
| Earnings from Continuing Operations | 50.63% | 42.89% | 31.84% | 20.08% | 17.88% |
| Earnings from Discontinued Operations | 89.39% | 97.78% | 87.37% | 91.86% | 72.72% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.35% | 54.71% | 44.50% | 36.13% | 28.02% |
| EBIT | 52.20% | 46.22% | 37.57% | 26.45% | 29.59% |
| EBITDA | 51.43% | 45.43% | 37.33% | 26.69% | 30.31% |
| EPS Basic | 74.56% | 69.64% | 55.56% | 49.09% | 45.05% |
| Normalized Basic EPS | 72.96% | 65.07% | 48.18% | 39.35% | 46.87% |
| EPS Diluted | 74.56% | 69.66% | 55.58% | 49.11% | 45.07% |
| Normalized Diluted EPS | 72.96% | 65.07% | 48.18% | 39.35% | 46.87% |
| Average Basic Shares Outstanding | 256.08% | 98.03% | 31.12% | 26.68% | 32.06% |
| Average Diluted Shares Outstanding | 256.08% | 98.03% | 31.12% | 26.68% | 32.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |